Lixte Biotechnology announces $3.5M registered direct offering at $6.00/share with warrants

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Issued 583,334 shares (or equivalents) at $6.00/share plus warrants for 583,334 shares at $6.00, expiring 5 years.
Gross proceeds ~$3.5M; placement agent A.G.P./Alliance Global Partners receives 6.0% fee and warrants at $6.60.
Common stock offered via effective shelf registration S-3 (No. 333-252430); warrants issued in private placement under Section 4(a)(2).
Closing expected July 20, 2023; 90-day lockup on further sales and 180-day prohibition on variable rate transactions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

LIXTE BIOTECHNOLOGY HOLDINGS, INC. entered into Securities Purchase Agreement valued at approximately $3,500,000 (effective 2023-07-18).

Action: entry
Agreement: equity purchase
Value: approximately $3,500,000
Effective: 2023-07-18

Exact text from the filing

On July 18, 2023, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchaser named therein (the “Purchaser”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Registered Offering”), 583,334 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) (or common stock equivalents in lieu thereof), and common warrants to purchase up to 583,334 shares of common stock in a concurrent private placement, at a purchase price of $6.00 per share.

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

LIXTE BIOTECHNOLOGY HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-025013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.